Jane Street Group LLC lessened its stake in Catalent (NYSE:CTLT) by 68.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,226 shares of the company’s stock after selling 11,171 shares during the quarter. Jane Street Group LLC’s holdings in Catalent were worth $215,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Meeder Asset Management Inc. lifted its stake in Catalent by 14.8% during the fourth quarter. Meeder Asset Management Inc. now owns 9,445 shares of the company’s stock valued at $388,000 after buying an additional 1,218 shares in the last quarter. First Bank & Trust raised its position in Catalent by 54.2% during the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after acquiring an additional 1,323 shares in the last quarter. SG Americas Securities LLC grew its holdings in Catalent by 4.1% during the fourth quarter. SG Americas Securities LLC now owns 39,984 shares of the company’s stock valued at $1,643,000 after purchasing an additional 1,579 shares during the last quarter. Strs Ohio grew its holdings in Catalent by 7.4% during the fourth quarter. Strs Ohio now owns 23,300 shares of the company’s stock valued at $957,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Eagle Boston Investment Management Inc. grew its holdings in Catalent by 40.0% during the fourth quarter. Eagle Boston Investment Management Inc. now owns 7,349 shares of the company’s stock valued at $306,000 after purchasing an additional 2,101 shares during the last quarter. Institutional investors own 99.89% of the company’s stock.
Several brokerages have recently issued reports on CTLT. Royal Bank of Canada set a $48.00 price objective on shares of Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Stephens cut Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. UBS raised Catalent from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 21st. Finally, Raymond James raised Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a report on Wednesday, March 21st. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Catalent presently has an average rating of “Buy” and an average price target of $45.75.
Catalent stock opened at $41.88 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. The stock has a market capitalization of $5,642.05, a price-to-earnings ratio of 31.02, a PEG ratio of 2.30 and a beta of 1.53. Catalent has a 12 month low of $27.95 and a 12 month high of $47.87.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. During the same period last year, the company earned $0.27 earnings per share. The firm’s revenue was up 25.3% compared to the same quarter last year. research analysts anticipate that Catalent will post 1.52 EPS for the current year.
In other Catalent news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the sale, the senior vice president now owns 46,986 shares of the company’s stock, valued at $1,964,014.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/21/catalent-ctlt-position-cut-by-jane-street-group-llc.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.